Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22458762 | 1.00 | EPHX1 (0.50) | EPHX1SIGMAR1HRH4HRH3L3MBTL1 | |
| SCHEMBL18458888 | 1.00 | EPHX1 (0.50) | EPHX1SIGMAR1HRH4HRH3L3MBTL1 | |
| SCHEMBL23841891 | 1.00 | EPHX1 (0.50) | EPHX1SIGMAR1HRH4HRH3L3MBTL1 | |
| SCHEMBL11293486 | 0.97 | EPHX1 (0.46) | EPHX1SIGMAR1HRH4HRH3L3MBTL1 | |
| SCHEMBL8222606 | 0.92 | — | — | |
| SCHEMBL754871 | 0.88 | HRH4 (0.45) | EPHX1SIGMAR1HRH4HRH3ADRB2 | |
| SCHEMBL841330 | 0.88 | HRH4 (0.45) | EPHX1SIGMAR1HRH4HRH3ADRB2 | |
| SCHEMBL4789143 | 0.88 | HRH4 (0.45) | EPHX1SIGMAR1HRH4HRH3ADRB2 | |
| SCHEMBL19350614 | 0.88 | HRH4 (0.45) | EPHX1SIGMAR1HRH4HRH3ADRB2 | |
| SCHEMBL2479475 | 0.88 | HRH4 (0.45) | EPHX1SIGMAR1HRH4HRH3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2021-05-06 | — | — | US | disclosed |
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2020-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588904-B2 | METAP2 inhibitors and methods of treating obesity | METAP2, ADIPOR2, METAP1 | EPHX1 3359/4885SIGMAR1 4814/4885HRH4 4730/4885 |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | EPHX1 2549/4885SIGMAR1 4435/4885HRH4 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.